Navigation Links
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments
Date:3/14/2012

ensure adequate time for any software download that may be necessary.

About LorcaserinLorcaserin is a new chemical entity that is believed to act as a selective serotonin 2C receptor agonist. The serotonin 2C receptor is expressed in the brain, including the hypothalamus, an area believed to be involved in the control of appetite and metabolism. Arena has patents that cover lorcaserin in the United States, Europe and other jurisdictions that in most cases are capable of continuing into 2023 without taking into account any patent term extensions or other exclusivity Arena might obtain.

Arena resubmitted to the FDA the lorcaserin NDA in December 2011, and the agency has assigned a new PDUFA target date of June 27, 2012. Eisai Inc. has exclusive rights to market and distribute lorcaserin in the United States subject to FDA approval of the lorcaserin NDA. An MAA for lorcaserin was filed with the EMA in March 2012. Arena currently owns rights to lorcaserin outside of the United States.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.

Arena Pharmaceuticals® and Arena® are registered service marks of the company.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the advancement, therapeutic indication and use, safety, efficacy, mechanism of action, and potential of lorcaserin; the regulatory review of the lorcaserin NDA resubmission and MAA, including the potential timing for the FDA to complete its review; the data, analyses and other information included in the NDA resubmission,
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Wednesday, March 14
2. Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control
3. Arena Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
4. Arena Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Lorcaserin
5. Arena Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
6. Arena Submits Response to FDA Complete Response Letter for Lorcaserin
7. Arena Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference
8. Arena Pharmaceuticals to Present at the Piper Jaffray 23rd Annual Health Care Conference
9. Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results
10. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
11. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DALLAS , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com ... to its store . (Photo: ... consumption upgrade and policy support, China,s ... the years, with total market size rising from 3.28 ...
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ( ... "Dental Consumables Market - Global Industry Analysis, Size, Share, ... to their offering. (Logo: ... which are used on patients in order to treat ...
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation today announced it ... adults suffering from the severe cold weather that has gripped ... to helping those in need; so to support these emergency ... up to $250,000, which could mean up to $500,000 in ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3
... Study Ingredient,s, Impact on North Americans, NEW ... of,Japan today announced that it has selected world-renowned Cardiologist ... KGK Synergize Inc.,to launch a new clinical trial to ... lipid management and the reduction of cardiovascular,risk factors in ...
... a 52-week phase 3,study (LEADTM 3) of Novo ... GLP-1 analog, were published online today in The ... produces statistically,significant and sustained improvements in blood sugar ... compared with glimepiride, a widely used,oral anti-diabetic drug. ...
Cached Medicine Technology:Leading Cardiologist Joins Ontario Research Firm to Conduct New Clinical Trial on the Effect of Pantethine on Cholesterol Levels 2Leading Cardiologist Joins Ontario Research Firm to Conduct New Clinical Trial on the Effect of Pantethine on Cholesterol Levels 3Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet 2Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet 3
(Date:7/11/2014)... Steven Reinberg HealthDay Reporter ... depression may increase the risk for stroke, a new study ... the risk of a stroke or a transient ischemic ... apparently raised stroke or TIA risk by 59 percent. And ... a mini-stroke caused by a temporary blockage of blood flow ...
(Date:7/11/2014)... the distinguished wedding dress manufacturer and retailer, has recently ... . To top it all off, all these high ... to 65% off. Clients who place orders on the ... Fadhits.com is devoted to designing and selling beautiful wedding ... All its items come with very fast delivery. More ...
(Date:7/11/2014)... San Francisco shows that an "expressive therapy" group ... living with HIV disclose their health status and ... and quality of their relationships., "Medication alone is ... L. Machtinger, MD, director of the Women,s HIV ... patients are on effective antiretroviral therapy but far ...
(Date:7/11/2014)... 11, 2014 Bedros Keuilian is known in ... he’s earned by founding the fast-selling fitness franchise in the ... businesses. He works with successful boot camp owners on a ... the traits of the most successful boot camp owners , ... qualities. , “I’ve worked with and coached some of the ...
(Date:7/11/2014)... When the mercury rises, heat can strain the limits of ... on a heavier load in hot weather to keep body ... Harvard Men's Health Watch . , For otherwise fit, ... their limits and drinking enough fluids. But what about men ... to the heat," says Dr. Joanne Foody, Director of cardiovascular ...
Breaking Medicine News(10 mins):Health News:Stress, Depression May Boost Stroke Risk, Study Finds 2Health News:Stress, Depression May Boost Stroke Risk, Study Finds 3Health News:Elegant Lace Holiday Dresses Released by Fadhits.com 2Health News:'Expressive therapy" intervention assists women living with HIV 2Health News:Fitness Boot Camp Marketing Expert Bedros Keuilian Shares the Top Three Traits of Successful Boot Camp Owners 2Health News:Fitness Boot Camp Marketing Expert Bedros Keuilian Shares the Top Three Traits of Successful Boot Camp Owners 3Health News:Take Common Sense Steps to Stay Safe This Summer, from the July 2014 Harvard Men's Health Watch 2Health News:Take Common Sense Steps to Stay Safe This Summer, from the July 2014 Harvard Men's Health Watch 3
... is a form of arthritis where one or more ... in these type of joint problems is the loss ... that moisturizes the area. This fluid is called synovial ... since 1987, after the therapy was proved beneficial in// ...
... Institute, has succeeded in finding a new biosensor ... a breakthrough technology that will help scientific researchers ... of neurons, nerve tissue and organic neural networks. ... metal oxide semiconductor technology extended with additional process ...
... currently testing the safety of hypothermia as a ... treatment has been shown to be effective for ... effectiveness in treating children with traumatic brain injuries ... excitotoxicity (excessive neurotransmitters released with injury that damage ...
... of Durham in England has reported a discovery, that adds ... ones, for breast feeding of babies. Babies who are breast-fed ... than babies who are bottle-fed in bed. The study included ... while they slept. Researchers found that mothers who breast-fed their ...
... received a patient, a two-month-old baby with white blood! The ... caused due to a deficiency of lipoprotein lipase. This disease ... said that the baby was brought to the hospital with ... boy child, was found to have lipemic blood. Doctors said ...
... study published in the journal, Molecular Psychiatry suggested that scientists ... to sleepwalking. Sleepwalking is a complex disorder and affects around ... of adults. Though the condition is harmless, it may sometimes ... others. Scientists examined a family of genes known as HLA ...
Cached Medicine News:
... is an effective angina relief ... poor targets. Because it is ... the CO2 Heart Laser 2 ... timely operative decisions to revascularize ...
Ultrasensitive TSH EIA Thyroid Function 025-BC-1003...
TG (Ab) RIA Thyroid Function 014-HD 27.1 Thyroglobulin...
... The anti-TG test kit is a solid ... format. It is designed for the quantitative ... (TG) in serum or plasma. The microplate ... Calibrators, controls and patient samples are pipetted ...
Medicine Products: